Share Buyback Program Authorized by Inspira Technologies OXY B.H.N. (NASDAQ:QTEX)

Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) declared that its board has authorized a share repurchase plan on Monday, June 22nd, RTT News reports. The company plans to repurchase 2,000,000,000,000 shares. This repurchase authorization allows the company to reacquire up to 5.6% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

QTEX has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Inspira Technologies OXY B.H.N. to a “hold” rating in a report on Saturday. Weiss Ratings initiated coverage on Inspira Technologies OXY B.H.N. in a research report on Wednesday, May 27th. They set a “sell (e+)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Inspira Technologies OXY B.H.N. Price Performance

Shares of QTEX remained flat at $2.01 during trading hours on Monday. 12,783,453 shares of the stock traded hands, compared to its average volume of 45,882,472. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.30 and a current ratio of 1.56. Inspira Technologies OXY B.H.N. has a 52 week low of $0.28 and a 52 week high of $3.85.

Inspira Technologies OXY B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.